Ganglionic blocking agents appear to be the most potent therapeutic agents for reducing the blood pressure in patients with severe hypertension. However, the orthostatic effect and the variability in blood pressure response to currently available ganglionic blocking agents are the most serious limiting factors in the use of these agents and may completely prohibit their use in some patients. Concurrent administration of rauwolfia, which depresses the sympathetic nervous system in the brain, partially stabilizes the blood pressure response. However, even then extreme variability frequently exists, apparently due to incomplete and variable absorption of these agents (hexamethonium and pentolinium) from the gastrointestinal tract.*
Recently another long-acting gangionic blocking agent has become available for clinical trial.† This compound, mecamy- lamine,‡ is a secondary amine (rather than a quaternary compound) which is completely absorbed from the gastrointestinal tract. For this reason it has been investigated as a therapeutic agent for reducing the blood
MOYER JH, FORD R, DENNIS E, et al. Drug Therapy (Mecamylamine) of Hypertension: III. Results with Mecamylamine, a Completely Absorbed Ganglionic Blocking Agent. AMA Arch Intern Med. 1956;98(2):187–210. doi:10.1001/archinte.1956.00250260061008
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: